Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 7
2018 27
2019 49
2020 48
2021 51
2022 42
2023 12
2024 1

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 32871795

196 results

Results by year

Filters applied: . Clear all
Page 1
Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program.
Verzoni E, Cartenì G, Cortesi E, Giannarelli D, De Giglio A, Sabbatini R, Buti S, Rossetti S, Cognetti F, Rastelli F, Sobrero A, Turci D, Sternberg CN, Porta C, Cappuzzo F, Tortora G, Tassinari D, Panni S, Pazzola A, Surico G, Raimondi A, De Giorgi U, Procopio G; Italian Nivolumab Renal Cell Cancer Early Access Program group. Verzoni E, et al. J Immunother Cancer. 2019 Apr 3;7(1):99. doi: 10.1186/s40425-019-0579-z. J Immunother Cancer. 2019. PMID: 30944023 Free PMC article.
Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort.
Naqash AR, Ricciuti B, Owen DH, Florou V, Toi Y, Cherry C, Hafiz M, De Giglio A, Muzaffar M, Patel SH, Sugawara S, Burkart J, Park W, Chiari R, Sugisaka J, Otterson GA, de Lima Lopes G, Walker PR. Naqash AR, et al. Cancer Immunol Immunother. 2020 Jul;69(7):1177-1187. doi: 10.1007/s00262-020-02536-5. Epub 2020 Mar 5. Cancer Immunol Immunother. 2020. PMID: 32140762
Correlation Between Immune-related Adverse Event (IRAE) Occurrence and Clinical Outcome in Patients With Metastatic Renal Cell Carcinoma (mRCC) Treated With Nivolumab: IRAENE Trial, an Italian Multi-institutional Retrospective Study.
Vitale MG, Pipitone S, Venturelli M, Baldessari C, Porta C, Iannuzzi F, Basso U, Scagliarini S, Zucali PA, Galli L, Rossetti S, Caserta C, Bracarda S, Iacovelli R, Masini C, Cortellini A, Di Girolamo S, Buti S, Fornarini G, Carrozza F, Santoni M, Caputo F, Giaquinta S, Balduzzi S, D'Amico R, Vitale G, Mighali P, Sabbatini R. Vitale MG, et al. Clin Genitourin Cancer. 2020 Dec;18(6):477-488. doi: 10.1016/j.clgc.2020.05.010. Epub 2020 May 20. Clin Genitourin Cancer. 2020. PMID: 32732112
Occurrence and number of immune-related adverse events are independently associated with survival in advanced non-small-cell lung cancer treated by nivolumab.
Bouhlel L, Doyen J, Chamorey E, Poudenx M, Ilie M, Gal J, Guigay J, Benzaquen J, Marquette CH, Berthet JP, Mouroux J, Schiappa R, Padovani B, Hofman P, Otto J. Bouhlel L, et al. Bull Cancer. 2020 Sep;107(9):946-958. doi: 10.1016/j.bulcan.2020.04.019. Epub 2020 Jul 6. Bull Cancer. 2020. PMID: 32646604
Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis.
Ricciuti B, Genova C, De Giglio A, Bassanelli M, Dal Bello MG, Metro G, Brambilla M, Baglivo S, Grossi F, Chiari R. Ricciuti B, et al. J Cancer Res Clin Oncol. 2019 Feb;145(2):479-485. doi: 10.1007/s00432-018-2805-3. Epub 2018 Dec 1. J Cancer Res Clin Oncol. 2019. PMID: 30506406
196 results